Novavax (NVAX) Free Cash Flow Growth (3y) (2013 - 2026)
Novavax (NVAX) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - | - |
| 10 | Novavax | 1.24 Bn | 447.27 Mn | 108.82 Mn | 53.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.24% |
| Dec 31, 2025 | 7.02% |
| Sep 30, 2025 | 44.88% |
| Jun 30, 2025 | 6.15% |
| Mar 31, 2025 | -21.11% |
| Dec 31, 2024 | 17.22% |
| Sep 30, 2024 | 1.88% |
| Jun 30, 2024 | 36.22% |
| Mar 31, 2024 | -28.66% |
| Dec 31, 2023 | -6.37% |
| Sep 30, 2023 | -73.88% |
| Jun 30, 2023 | -52.46% |
| Mar 31, 2023 | -142.01% |
| Dec 31, 2022 | -35.99% |
| Sep 30, 2022 | -47.53% |
| Jun 30, 2022 | -70.47% |
| Mar 31, 2022 | -27.52% |
| Dec 31, 2021 | -89.19% |
| Sep 30, 2021 | -65.24% |
| Jun 30, 2021 | 72.30% |